文献速递妇科

每周紫杉醇对比西地尼布-奥拉帕利(连续或间歇方案)治疗铂耐药高级别上皮性卵巢癌的随机II期试验

Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2022-01-19

BAROCCO试验随机纳入123例铂耐药高级别上皮性卵巢癌患者,比较每周紫杉醇、西地尼布-奥拉帕利连续方案和间歇方案的疗效。连续方案与对照组的中位无进展生存期分别为5.6个月和3.1个月,风险比为0.76(90% CI 0.50-1.14,p=0.265),间歇方案为3.8个月,风险比为1.03(90% CI 0.68-1.55,p=0.904)。西地尼布-奥拉帕利联合方案在无进展生存期方面未优于化疗,但口服双药具有活性,可能为这一难治人群提供非化疗选择。

要点

  • 连续方案与对照组的中位无进展生存期分别为5.6个月和3.1个月,风险比为0.76(90% CI 0.50-1.14,p=0.265)。
  • 间歇方案与对照组的中位无进展生存期分别为3.8个月和3.1个月,风险比为1.03(90% CI 0.68-1.55,p=0.904)。
  • 西地尼布-奥拉帕利联合方案在无进展生存期方面未优于化疗,但口服双药具有活性,可能提供非化疗选择。

核心结论

  • 在经重度治疗的铂耐药卵巢癌患者中,西地尼布-奥拉帕利联合方案在无进展生存期方面未优于化疗。
  • 该口服双药具有活性,可能为这一难治人群提供非化疗选择。

研究设计与样本

  • BAROCCO试验为随机II期试验,共随机纳入123例患者。
  • 对照组为每周紫杉醇80mg/m2,最多24周。
  • 连续方案组为奥拉帕利300mg片剂每日两次联合西地尼布20mg每日一次,直至疾病进展。
  • 间歇方案组为奥拉帕利300mg片剂每日两次联合西地尼布20mg每周5天,直至疾病进展。
  • 主要目标为比较每个试验组与对照组的无进展生存期(单侧α=5%,把握度80%,风险比0.5)。

主要发现

  • 中位无铂间期为1.9个月,60%的患者既往接受过3线或以上化疗。
  • 紫杉醇组、连续方案组和间歇方案组的中位无进展生存期分别为3.1个月、5.6个月和3.8个月。
  • 连续方案组对比对照组的无进展生存期风险比为0.76(90% CI 0.50-1.14,p=0.265)。
  • 间歇方案组对比对照组的无进展生存期风险比为1.03(90% CI 0.68-1.55,p=0.904)。
  • 因不良事件停止治疗的患者比例在对照组、连续方案组和间歇方案组分别为15%、20%和5%。

临床怎么用

  • 作者认为,西地尼布-奥拉帕利联合方案在无进展生存期方面未优于化疗,但该口服双药具有活性,可能为这一难治人群提供非化疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous findings showed that cediranib-olaparib increased PFS in women with recurrent platinum-sensitive ovarian cancer compared to olaparib alone. METHODS: BAROCCO trial randomized 123 patients: 80mg/m2 paclitaxel weekly up to 24 weeks (control), olaparib 300mg tablets twice daily together with 20mg cediranib daily (continuous schedule) or with 20mg cediranib 5 days/week (intermittent schedule) until progression. The primary objective was the PFS comparison between each experimental arm and the control (alpha one-sided 5%; power 80%; HR 0.5). RESULTS: The median platinum-free interval was 1.9 months, 60% of patients had been pretreated with 3 or more chemotherapy lines. Median PFS for paclitaxel, the continuous, and the intermittent schedules were 3.1, 5.6, and 3.8 months. The HR for PFS in the continuous arm vs control was 0.76 (90% CI: 0.50-1.14, p = 0.265). The HR for PFS in the intermittent arm vs control was 1.03 (90% CI: 0.68-1.55, p = 0.904). Treatment was discontinued due to adverse events in 15%, 20%, and 5% of patients in the control, continuous and intermittent arms. Grade ≥ 3 anemia and diarrhea and hypertension of any grade occurred only in the experimental arms, and peripheral neuropathies and alopecia only in the control arm. Five serious adverse drug reactions occurred and two were fatal: one in the control and one in the continuous arm. CONCLUSIONS: The combination of cediranib-olaparib was not superior to chemotherapy in terms of PFS in heavily pretreated platinum-resistant ovarian cancer patients. However, this oral doublet, is active and may offer a non-chemotherapy option in this difficult to treat population. CLINICAL TRIAL IDENTIFICATION: IRFMN-OVA-7289, EudraCT: 2016-003964-38, NCT03314740.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Colombo N, Tomao F, Benedetti Panici P, et al. Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer. Gynecol Oncol. 2022. PMID: 35063281. doi:10.1016/j.ygyno.2022.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。